CoChat

Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection

Andreasen, Christine Rode, Andersen, Andreas, Knop, Filip Krag, Vilsbøll, Tina · 2021 · Diabetes, Obesity and Metabolism
Cited by 38

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Since the first glucagon‐like peptide 1 (GLP‐1) receptor agonist (GLP‐1RA) was approved in 2005 (exenatide twice daily) for type 2 diabetes (T2D), the class has developed with newer compounds having more pronounced effects on glycaemic control and body weight. Also, administration regimes have become more convenient with once weekly injections, and recently an oral administration has become available. Large‐scale randomized controlled cardiovascular (CV) outcome trials (CVOTs) have shown that GLP‐1RA therapy can reduce the risk of CV disease (CVD) in high‐risk individuals with T2D. In addition, GLP‐1RAs may have renal benefits driven by new‐onset macroalbuminuria, although no effect on hard renal endpoints has been found. Subsequently, the place for GLP‐1RA therapy has changed over recent years, with most societies endorsing GLP‐1RA therapy in patients with established or high risk of CVD independently of glycaemia. Initiation of GLP‐1RA therapy can be complex due to differences in efficacy, side effects and safety profiles as well as administration forms within the class. Implementing guideline recommendations into ideal patient selection may be challenging both in specialty and non‐specialty settings. To ensure adequate and proactive use of modern glucose‐lowering medications in the treatment of T2D, it is essential to recognize patients with high risk or documented CVD. The present review provides an overview of the efficacy and benefits of the currently available GLP‐1RA compounds. Furthermore, we review the results from recent large‐scale CVOTs in a clinical context and suggest improving the implementation of GLP‐1RA therapy across specialties to improve overall patient selection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14500

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 38

Metadata

Authors
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2021-09
Volume
23
Issue
S3
Pages
40-52
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3200932276
Cited by
38
References
48
FWCI
3.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. https://app.cochat.ai/papers/10.1111/dom.14500
The paper
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021). Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.